DOR - Steve Kanzer Resignation from Board of Directors
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): May
28, 2007
Commission
File No. 000-16929
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1101
Brickell Ave., Suite 701 S
Miami,
FL
|
|
33131
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(786)
425-3848
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item 5.02. Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On
May
28, 2007, Steven H. Kanzer resigned as a member of the Company’s board of
directors (the “Board”). Mr. Kanzer was Vice-Chairman of the Board and a member
of the audit, compensation and nominating committees of the Board. A copy of
Mr.
Kanzer’s letter of resignation is filed herewith as Exhibit 99.1.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Exhibit
No. Title
99.1 Letter
of
Resignation dated May 28, 2007.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA, INC.
By:
/s/
Christopher J. Schaber
Name:
Christopher J. Schaber
Title:
Chief Executive Officer
Date:
May
28, 2007